Valence Advantage Life Sciences Fund: CalciMedica Raises $15M in Series C Financing

CalciMedica Inc., a La Jolla, Calif.-based clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, raised $15m in Series C financing. The round was led by Valence Life Sciences, with participation from new investors Bering Capital, Mesa Verde Venture Partners and existing investor Sanderling Ventures. The [...]The post CalciMedica Raises $15M in Series C Financing appeared first on FinSMEs.